Major depressive disorder (MDD) affects hundreds of millions worldwide and varies by sex and age, with about 5% of adults affected (and 5.7% among adults over 60). It is defined by symptoms like depressed mood or anhedonia lasting at least two weeks, along with other DSM-5 features. This page covers prevalence, core diagnostic criteria, common symptom patterns, key risk factors, and how treatments such as antidepressants, CBT, and ECT influence outcomes.
Key Takeaways
- 50% of MDD patients relapse within 6 months after first remission
- MDD increases all-cause mortality risk by 1.8-2.2 fold
- Suicide attempt rate in MDD is 15-20% lifetime
- Approximately 280 million people in the world have depression, including 5% of adults (4% among men and 6% among women), and 5.7% of adults older than 60 years
- In the United States, the 12-month prevalence of major depressive disorder (MDD) among adults aged 18 and over in 2021 was 8.3%
- Lifetime prevalence of MDD in the US is estimated at 20.6% for adults, with higher rates in women at 24.6% compared to 14.8% in men
- Female gender increases MDD risk 1.5-3 fold compared to males
- Family history of MDD doubles the risk (OR 2.0-4.0)
- Childhood adversity (abuse/neglect) increases MDD risk by 2.5 times (OR 2.7)
- The core symptom of MDD is persistent depressed mood or loss of interest/pleasure (anhedonia) present for at least 2 weeks
- MDD requires at least 5 of 9 DSM-5 symptoms nearly every day for 2 weeks, including depressed mood or anhedonia
- Somatic symptoms like fatigue (73%), sleep disturbance (77%), and appetite change (69%) are common in MDD
- Antidepressants remit 40-60% of first-episode MDD cases
- Cognitive Behavioral Therapy (CBT) achieves 50% response rate in MDD, superior to waitlist
- SSRIs like sertraline remit 50-65% of MDD at 8 weeks, NNT=4-5
MDD affects hundreds of millions, raises mortality, and despite treatment many relapse quickly without sustained care.
Related reading
01 · Category
Outcomes And Impacts29 stats
01
50% of MDD patients relapse within 6 months after first remission
02
MDD increases all-cause mortality risk by 1.8-2.2 fold
03
Suicide attempt rate in MDD is 15-20% lifetime
04
MDD accounts for 800,000 suicides annually worldwide
05
Functional disability: 60% of MDD patients unable to work during episodes
06
MDD reduces life expectancy by 7-11 years on average
07
Healthcare costs for MDD in US $210 billion annually (2020)
08
Chronic MDD (>2 years) in 20-30% of cases, poor prognosis
09
Comorbid MDD doubles cardiovascular disease risk (HR 2.0)
10
Absenteeism: MDD causes 200 million lost workdays/year in US
11
Remission rates drop to 30% after 3 failed treatments (TRD)
12
MDD in adolescence predicts adult chronicity in 40%
13
Global economic burden of depression $1 trillion/year in lost productivity
14
Post-MDD divorce rate 2.5 times higher
15
Cognitive deficits persist in 30-50% after MDD remission
16
MDD increases dementia risk by 80-90% (HR 1.9)
17
Unemployment rate twice as high in MDD (OR 2.0)
18
Maternal MDD affects child development: 2-4 fold behavior problems
19
Treatment-resistant MDD (30%) has 10-year functionality like schizophrenia
20
MDD hospitalizations: 4 million/year in US
21
Recovery rate first episode 70%, but only 20% never recur
22
MDD linked to 50% increased stroke risk (RR 1.45)
23
Social functioning impaired in 75% during MDD episodes
24
Perinatal MDD recurrence 25% in subsequent pregnancies
25
MDD patients have 2.5 fold higher type 2 diabetes incidence
26
Lost productivity from MDD $44 billion/year in US (direct+indirect)
27
Suicide completion rate in MDD 4-15%
28
Brain volume loss: Hippocampus 10-15% smaller in chronic MDD
29
Quality-adjusted life years (QALYs) lost: MDD causes 50 million globally/year
Interpretation
Outcomes And Impacts Interpretation
From an outcomes and impacts perspective, major depressive disorder shows a relentless course and severe harm with 50% of patients relapsing within 6 months and a reduction in life expectancy of 7 to 11 years, alongside a markedly higher mortality risk of 1.8 to 2.2 times and a major global burden of 800,000 suicides each year.
02 · Category
Prevalence And Epidemiology30 stats
01
Approximately 280 million people in the world have depression, including 5% of adults (4% among men and 6% among women), and 5.7% of adults older than 60 years
02
In the United States, the 12-month prevalence of major depressive disorder (MDD) among adults aged 18 and over in 2021 was 8.3%
03
Lifetime prevalence of MDD in the US is estimated at 20.6% for adults, with higher rates in women at 24.6% compared to 14.8% in men
04
Globally, depression was the fourth leading cause of disability in 2021, accounting for 7.5% of all years lived with disability (YLDs)
05
Among US adolescents aged 12-17, the prevalence of MDD in the past year was 20.1% in 2021
06
In Europe, the pooled prevalence of MDD across 27 studies was 6.4% (95% CI 5.8-7.1%)
07
During the COVID-19 pandemic, global prevalence of depressive disorders increased by 27.6% from 2019 to 2020
08
In low- and middle-income countries, the prevalence of MDD is around 5.5%, but underdiagnosis leads to lower reported rates
09
Among US college students, the 12-month prevalence of MDD was 22.7% in 2020-2021
10
In the UK, 4.4% of the population aged 16+ experienced depressive episode in the past week in 2014
11
Prevalence of MDD in US primary care settings is 10-20%
12
Globally, over 264 million people suffer from depression as of 2017 estimates
13
In Australia, 1 in 6 people (16.5%) aged 16-85 experienced depression in their lifetime
14
Among US adults aged 18-25, past-year MDD prevalence was 21.0% in 2021
15
In Japan, lifetime prevalence of MDD is 7.9% for men and 12.7% for women
16
During pregnancy, prevalence of MDD is 10-15% worldwide
17
In the US military, past-year MDD prevalence is 5.4%
18
Among US Hispanics, lifetime MDD prevalence is 17.6%
19
In Canada, 4.7% of the population aged 15+ reported MDD in 2012
20
Globally, depression affects 322 million people as per 2015 data
21
In South Africa, lifetime prevalence of MDD is 9.8%
22
Among US adults with chronic pain, MDD prevalence is 20-35%
23
In India, community prevalence of MDD is 5.3%
24
Past-month MDD prevalence among US adults was 6.7% in 2019
25
In Brazil, 12-month MDD prevalence is 5.8%
26
Among US veterans, lifetime MDD prevalence is 14.5%
27
In China, point prevalence of MDD is 1.8%, but underdiagnosed
28
Among US incarcerated individuals, MDD prevalence is 16.8%
29
In New Zealand, 1 in 7 adults experience a mood disorder like MDD over their lifetime
30
Global incidence of depression increased by 25% during the first year of COVID-19
Interpretation
Prevalence And Epidemiology Interpretation
Depression affects a vast share of the population, with 280 million people worldwide and especially high prevalence in adolescents and women, such as US adolescents aged 12 to 17 reaching 20.1% in 2021 and US lifetime MDD running 24.6% in women versus 14.8% in men, underscoring the scale of the condition highlighted in prevalence and epidemiology.
03 · Category
Risk Factors And Causes27 stats
01
Female gender increases MDD risk 1.5-3 fold compared to males
02
Family history of MDD doubles the risk (OR 2.0-4.0)
03
Childhood adversity (abuse/neglect) increases MDD risk by 2.5 times (OR 2.7)
04
Heritability of MDD is 31-42% from twin studies
05
Chronic stress elevates cortisol, increasing MDD risk by 2-3 fold
06
Obesity (BMI>30) associated with 55% higher MDD risk (RR 1.55)
07
Smoking increases MDD incidence by 2 fold
08
Low socioeconomic status raises MDD risk by 1.5-2.5 times
09
Postpartum period increases MDD risk 10-15% in first year
10
Comorbid anxiety disorders increase MDD risk 3-5 fold
11
Sleep disorders precede MDD onset in 40% of cases (OR 2.1)
12
Childhood trauma meta-analysis shows OR 2.8 for MDD
13
Genetic variants in serotonin transporter (5-HTTLPR) interact with stress for MDD (OR 2.4)
14
Urban living increases MDD risk by 21% vs rural (OR 1.21)
15
Divorce/widowhood raises MDD risk 2-3 times
16
Chronic medical illness (e.g., diabetes) OR 1.8 for MDD
17
Alcohol use disorder comorbidity OR 3.7 for MDD
18
Inflammation markers (CRP>3mg/L) predict MDD onset (HR 1.45)
19
Adverse childhood experiences (ACE score ≥4) OR 4.6 for adult MDD
20
Hypothalamic-pituitary-adrenal (HPA) axis hyperactivity in 50-60% of MDD
21
Parental depression increases child MDD risk 2-4 fold
22
Shift work disrupts circadian rhythm, OR 1.4 for MDD
23
Bullying victimization in adolescence OR 2.1 for later MDD
24
Lead exposure in childhood increases MDD risk 1.5 fold
25
Social isolation OR 1.9 for incident MDD
26
Perfectionism trait OR 2.0 for MDD onset
27
BDNF Val66Met polymorphism associated with MDD susceptibility (OR 1.3)
Interpretation
Risk Factors And Causes Interpretation
Across the risk factors and causes of MDD, women face a 1.5 to 3 fold higher risk and childhood adversity raises risk about 2.5 times, while heritability from twin studies is 31 to 42 percent, showing both environmental and biological drivers.
More related reading
04 · Category
Symptoms And Diagnosis29 stats
01
The core symptom of MDD is persistent depressed mood or loss of interest/pleasure (anhedonia) present for at least 2 weeks
02
MDD requires at least 5 of 9 DSM-5 symptoms nearly every day for 2 weeks, including depressed mood or anhedonia
03
Somatic symptoms like fatigue (73%), sleep disturbance (77%), and appetite change (69%) are common in MDD
04
Cognitive symptoms in MDD include impaired concentration (60-70%) and indecisiveness
05
Psychomotor agitation or retardation occurs in 40-50% of MDD patients
06
Feelings of worthlessness or excessive guilt are reported by 50-65% of individuals with MDD
07
Recurrent thoughts of death or suicidal ideation are present in 50% of MDD cases
08
Atypical depression features include hypersomnia (over 10 hours/day) and hyperphagia in 15-30% of MDD
09
Melancholic MDD subtype shows profound anhedonia and diurnal mood variation worse in morning in 25-30%
10
PHQ-9 score of 10 or higher has 88% sensitivity and 88% specificity for MDD diagnosis
11
Hamilton Depression Rating Scale (HAM-D) scores >17 indicate moderate-severe MDD, used in 70% of trials
12
MADRS scale sensitivity for MDD is 71-89%, focusing on core mood symptoms
13
Insomnia occurs in 75% of MDD patients, hypersomnia in 20%
14
Psychotic features in severe MDD (psychotic depression) occur in 15-25% of hospitalized cases
15
Anxiety symptoms co-occur in 60% of MDD cases, complicating diagnosis
16
Somatic complaints without clear medical cause are initial presentation in 69% of primary care MDD
17
Seasonal pattern specifier for MDD affects 10% of cases with winter worsening
18
Perinatal MDD symptoms include irritability and anxiety in 50% of cases beyond sadness
19
In children, MDD often presents as irritability rather than sadness in 60-80%
20
Composite International Diagnostic Interview (CIDI) for MDD has kappa reliability of 0.61-0.78
21
Beck Depression Inventory (BDI-II) cutoff of 14+ detects MDD with 85% sensitivity
22
Catatonia in MDD occurs in 10-15% of severe cases
23
Mixed features specifier (manic symptoms with MDD) in 25% of cases per DSM-5
24
Pain symptoms in MDD: headache (38%), back pain (35%), abdominal pain (30%)
25
Diagnostic delay for MDD averages 7-10 years from symptom onset
26
45% of MDD patients have suicidal ideation at diagnosis
27
Neurovegetative symptoms (sleep, appetite, energy) disrupted in 80-90% of MDD
28
Emotional numbing reported in 50% of MDD beyond anhedonia
29
DSM-5 remission requires ≤1 symptom for 2 months post-treatment
Interpretation
Symptoms And Diagnosis Interpretation
For MDD diagnosis, the hallmark is depressed mood or anhedonia lasting at least 2 weeks, and clinicians also look for 5 or more of the 9 DSM-5 symptoms nearly every day during that period while somatic and cognitive issues are common, such as sleep disturbance in 77% and impaired concentration in about 60 to 70%.
05 · Category
Treatment And Management28 stats
01
Antidepressants remit 40-60% of first-episode MDD cases
02
Cognitive Behavioral Therapy (CBT) achieves 50% response rate in MDD, superior to waitlist
03
SSRIs like sertraline remit 50-65% of MDD at 8 weeks, NNT=4-5
04
ECT remission rates 70-90% in severe MDD, but relapse 50% in 6 months without maintenance
05
Mindfulness-Based Cognitive Therapy (MBCT) reduces relapse by 43% in recurrent MDD
06
TMS (rTMS) response rate 50-60% in treatment-resistant MDD
07
Ketamine IV infusion (0.5mg/kg) 70% response in 24 hours for TRD
08
Exercise (150 min/week moderate) reduces MDD symptoms by 0.4-0.6 SMD
09
Interpersonal Psychotherapy (IPT) remission 50% in 16 weeks for MDD
10
Bupropion smoking cessation aid also treats MDD with 60% response
11
Psilocybin-assisted therapy 71% response in TRD (2 doses)
12
Lithium augmentation in SSRI non-responders boosts remission 15-20%
13
Vagus Nerve Stimulation (VNS) 27% response at 12 months in TRD
14
Omega-3 fatty acids (1-2g EPA/day) adjunctive SMD 0.28 reduction in MDD
15
Collaborative care models in primary care improve MDD outcomes by 20-30%
16
SNRI venlafaxine 55-65% response rate similar to TCAs
17
Digital CBT apps remit 30-50% mild-moderate MDD
18
Esketamine nasal spray 69% response at 24h in TRD, FDA approved
19
Bright light therapy (10,000 lux 30min/day) 60% response in SAD-MDD
20
Psychodynamic therapy 40-50% remission in MDD
21
Augmentation with atypical antipsychotics (aripiprazole) 25% added response in TRD
22
Tai Chi Qigong reduces MDD symptoms SMD 0.75 vs controls
23
Stepped care models achieve 70% recovery at 12 months
24
Folate augmentation (L-methylfolate 15mg) 32% response boost in SSRI poor metabolizers
25
Group CBT 50% response rate, cost-effective for MDD
26
Deep Brain Stimulation (DBS) 45-60% response in severe TRD
27
St. John's Wort 50-70% response mild-moderate MDD, but interactions
28
Behavioral Activation Therapy 47-60% remission in MDD
Interpretation
Treatment And Management Interpretation
Across treatment and management options for MDD, response and remission rates are often substantial such as SSRIs remitting 50 to 65 percent at 8 weeks or ECT reaching 70 to 90 percent in severe cases, while preventing relapse requires the right ongoing strategy like MBCT cutting relapse by 43 percent in recurrent MDD.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Kevin O'Brien. (2026, February 13). Mdd Statistics. Gitnux. https://gitnux.org/mdd-statistics
MLA
Kevin O'Brien. "Mdd Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/mdd-statistics.
Chicago
Kevin O'Brien. 2026. "Mdd Statistics." Gitnux. https://gitnux.org/mdd-statistics.
Sources & references
20 datasets cited across this report · attribution is report-level